


Lifting All Boats: The Broad Benefits of Increased Investments in HIV/AIDS Research

In 2014, language included in every National Institutes of Health (NIH) budget since the early 1990s directing NIH to invest 10% of its funding in HIV research was removed. **In just four years (2014-2017), removal of this language has resulted in 600 million fewer dollars being available for NIH HIV research.** At the same time, inflation has shrunk the purchasing power of NIH HIV research dollars such that our ability to invest in new treatments, prevention tools, and, most importantly, a cure is **at its lowest since 2003.** HIV research has not only saved the lives of millions of people living with HIV, but has contributed to the development of new treatments and technologies for a broad range of diseases. Increases in the NIH HIV research budget lift all boats.

Declining Purchasing Power of NIH HIV/AIDS Research Dollars



Many new and experimental treatments for diseases such as cancer, hepatitis and Alzheimer's have arisen from **research on HIV/AIDS**. Here are just a few examples:



Drugs developed to treat HIV are now widely used to treat **hepatitis B**.



Researchers are investigating the use of protease inhibitors—first used to treat HIV—to treat **Alzheimer's disease**.



Experimental treatments for **several types of cancer** have grown directly out of AIDS research.



A new class of anti-HIV drug called a CCR5 inhibitor is being tested for the treatment of certain **autoimmune disorders**.



Tests developed to diagnose HIV are now routinely used to detect other diseases such as **hepatitis C, TB, and Lyme disease**.